GoodRx Holdings, the Healthcare sector company, was revisited by a Wall Street analyst on May 8. Analyst Stan Berenshteyn from Wells Fargo maintained a Buy rating on the stock and has a $3.50 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Stan Berenshteyn has given his Buy rating due to a combination of factors that highlight both resilience and improving growth drivers for GoodRx. He emphasizes that recent results confirm the company’s strategic shift toward higher-value segments, particularly Pharma Direct and subscription services, which are showing strong momentum and support the long-term consumer-direct thesis.
He also notes that while the Core Rx transactions business is under pressure and likely to remain a drag, the expanding contribution from Pharma Direct and subscriptions should increasingly offset this weakness over time. With revenue and adjusted EBITDA forecasts essentially unchanged and the mix expected to tilt away from the challenged core by 2027–2028, he views the current setup as attractive and maintains a Buy rating with an unchanged $3.5 price target.
In another report released on May 6, Raymond James also maintained a Buy rating on the stock with a $0.00 price target.